12/3
04:32 pm
mgx
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:13 am
mgx
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference [Yahoo! Finance]
High
Report
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference [Yahoo! Finance]
12/1
07:00 am
mgx
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
High
Report
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
11/27
02:50 pm
mgx
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
08:00 am
mgx
Metagenomi to Present at Jefferies Global Healthcare Conference in London
Medium
Report
Metagenomi to Present at Jefferies Global Healthcare Conference in London
11/11
04:26 pm
mgx
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates [Yahoo! Finance]
High
Report
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates [Yahoo! Finance]
11/11
04:11 pm
mgx
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development [Yahoo! Finance]
Medium
Report
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development [Yahoo! Finance]
11/11
04:02 pm
mgx
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
High
Report
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
11/11
04:01 pm
mgx
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
High
Report
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
10/31
01:04 pm
mgx
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/25
01:32 am
mgx
Low
Report
10/21
07:28 am
mgx
Metagenomi (NASDAQ:MGX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Metagenomi (NASDAQ:MGX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.